At a glance
ClinicalIndex Comparison RecordN/ACompleted· 34 enrolled
Drug / intervention
Omega-3 DHA +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Assess the Effects of DHA (Docosahexaenoic Acid) on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment
In Brief
A clinical study evaluating Omega-3 DHA and Placebo for Obesity and Inflammation. Completed, enrolled 34 participants across 1 site.
Detailed Summary
Comparative, randomized, placebo-controlled, single-centre, single-blind clinical trial to assess the effectiveness of providing additional DHA omega-3 fatty acids supplements to increase the levels of pro-resolving and anti-inflammatory lipid mediators and decrease the biological markers of chronic inflammation in obese patients following a weight-loss programme.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Inflammation
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionDec 2014
Study CompletionMar 2015
TodayJul 2026
First PostedMay 30, 2013
Enrollment StartMay 1, 2013
Primary CompletionDec 1, 2014
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.1 years ago
Interventions
Omega-3 DHAdietary
Patients take daily 2 tablets of Docosahexaenoic Acid
Placeboother
Patients in control group take daily 2 placebo capsule